Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Revenue (2016 - 2025)

Veracyte (VCYT) has disclosed Revenue for 14 consecutive years, with $140.6 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 18.55% to $140.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $517.1 million through Dec 2025, up 16.01% year-over-year, with the annual reading at $517.1 million for FY2025, 16.01% up from the prior year.
  • Revenue hit $140.6 million in Q4 2025 for Veracyte, up from $131.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $140.6 million in Q4 2025 to a low of $36.7 million in Q1 2021.
  • Historically, Revenue has averaged $92.0 million across 5 years, with a median of $90.2 million in 2023.
  • Biggest five-year swings in Revenue: surged 166.16% in 2021 and later rose 13.75% in 2025.
  • Year by year, Revenue stood at $67.3 million in 2021, then grew by 19.25% to $80.3 million in 2022, then rose by 22.29% to $98.2 million in 2023, then increased by 20.81% to $118.6 million in 2024, then increased by 18.55% to $140.6 million in 2025.
  • Business Quant data shows Revenue for VCYT at $140.6 million in Q4 2025, $131.9 million in Q3 2025, and $130.2 million in Q2 2025.